<?xml version="1.0" encoding="UTF-8"?>



<records>

  <record>
    <language>eng</language>
          <publisher>Oriental Scientific Publishing Company</publisher>
        <journalTitle>Biomedical and Pharmacology Journal</journalTitle>
          <issn>0974-6242</issn>
            <publicationDate>2015-10-25</publicationDate>
    
        <volume>8</volume>
        <issue>October Spl Edition</issue>

 
    <startPage>761</startPage>
    <endPage>766</endPage>

	 
      <doi>10.13005/bpj/780</doi>
        <publisherRecordId>4370</publisherRecordId>
    <documentType>article</documentType>
    <title language="eng">The Effect of Levodopa on Motor Function Outcome in Patients with Ischemic Stroke:  A Double-Blind, Placebo-Controlled, Randomized Clinical Trial</title>

    <authors>
	

	

	

	


	


	
    </authors>
    
	    <affiliationsList>
	    
		

		
		
		
		
		
	  </affiliationsList>






    <abstract language="eng">Levodopa enhances neuronal plasticity and functional recovery and modulates anatomical and functional variations in central nervous system. The present study was aimed to evaluate the effect of levodopa-C on motor function recovery of patients experienced a stroke. This was a randomized, placebo-controlled, double-blind clinical trial conducted on 114 patients with ischemic middle cerebral artery stroke. The patients after the first day of stroke were randomly divided into two groups: the levodopa-C group and placebo group. In addition to the intervention, the patients received the stroke routine medications during the study. The patients received 100 mg daily medication for 3 weeks. A significant improvement was observed in motor function criteria of Rivermead mobility index (RMI) (p = 0.006) and Barthel index (BI) (p = 0.009) after 21 days in the levodopa-C group (79.1 %), compared to the placebo group (49 %). A review was carried in the subgroups, which indicate that patients with cortical stroke in the levodopa group had a significant improvement, compared with the placebo group (p = 0.005). The basic motor functions of about 79 % of the levodopa-C patients (n = 35), compared with the 44% in the placebo group, were enhanced by 25% according to the BI and RMI criteria (p = 0.008). Most of these patients had cortical stroke. Our findings showed significant therapeutic effect of levodopa-C in the patients with cortical stroke. Larger clinical trials containing larger sample size with cortical ischemic stroke are needed to better assess the impact.</abstract>

    <fullTextUrl format="html">https://biomedpharmajournal.org/vol8octoberspledition/the-effect-of-levodopa-on-motor-function-outcome-in-patients-with-ischemic-stroke-a-double-blind-placebo-controlled-randomized-clinical-trial/</fullTextUrl>

<keywords language="eng">

      
        <keyword>Ischemic stroke</keyword>
      

      
        <keyword> levodopa–C</keyword>
      

      
        <keyword> Motor Function Improvement</keyword>
      

      
        <keyword> Middle Cerebral Artery</keyword>
      

      
        <keyword> Rivermead Mobility Index</keyword>
      

      
        <keyword> Barthel Index Clinical Trials</keyword>
      

      
        <keyword> Placebo</keyword>
      
</keywords>
  </record>
</records>